Table 2A.

TGFβ isoform expression in ovarian and FTE in subjects with and without levonorgestrel treatment

TissueTGFβ IsoformTreatmentMean stain intensity ± SD (95% CI)P
OvaryTGFβ1Placebo0.95 ± 1.11 (0.43–1.47)
Levonorgestrel1.46 ± 1.22 (0.99–1.92)0.139
TGFβ2Placebo2.29 ± 1.01 (1.89–2.68)
Levonorgestrel2.32 ± 1.09 (1.90–2.74)0.899
TGFβ3Placebo1.50 ± 1.31 (1.01–1.99)
Levonorgestrel1.52 ± 1.26 (1.05–1.98)0.961
FallopianTGFβ1Placebo1.67 ± 1.15 (1.21–2.14)
tubeLevonorgestrel2.12 ± 1.33 (1.63–2.63)0.185
TGFβ2Placebo2.45 ± 1.05 (2.06–2.84)
Levonorgestrel2.67 ± 0.90 (2.35–2.99)0.374
TGFβ3Placebo2.25 ± 1.02 (1.87–2.63)
Levonorgestrel2.16 ± 1.26 (1.70–2.61)0.748
  • Abbreviation: CI, confidence interval.